Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjects.

Scoppetta M, Di Gennaro G, Scoppetta C.

Eur Rev Med Pharmacol Sci. 2005 Nov-Dec;9(6):343-8.

PMID:
16479738
2.

Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.

Judge R, Parry MG, Quail D, Jacobson JG.

Int Clin Psychopharmacol. 2002 Sep;17(5):217-25.

PMID:
12177584
3.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

4.

Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.

Serrano-Blanco A, Pinto-Meza A, Suárez D, Peñarrubia MT, Haro JM; ETAPS Group (Efectivitat del Tractament antidepressiu en Atenció Primària de Salut)..

Acta Psychiatr Scand Suppl. 2006;(432):39-47.

PMID:
17087814
5.

[Withdrawal syndrome caused by selective serotonin reuptake inhibitors: apropos of a case].

Bryois C, Rubin C, Zbinden JD, Baumann P.

Praxis (Bern 1994). 1998 Mar 4;87(10):345-8. Review. French.

PMID:
9545842
6.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
8.

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.

Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1034-7. Epub 2007 Mar 7.

PMID:
17459550
9.

Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine.

Kalin NH, Davidson RJ, Irwin W, Warner G, Orendi JL, Sutton SK, Mock BJ, Sorenson JA, Lowe M, Turski PA.

J Clin Psychiatry. 1997;58 Suppl 16:32-9.

10.

Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization.

Sheffield RE, Lo Sasso AT, Young CH, Way K.

Adm Policy Ment Health. 2002 Nov;30(2):121-39.

PMID:
12680617
13.

A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.

Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M.

Clin Neuropharmacol. 2007 Nov-Dec;30(6):326-34.

PMID:
18090457
14.

Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.

Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E.

Psychiatry Clin Neurosci. 2006 Oct;60(5):605-10.

15.

Antidepressant therapy and C-reactive protein levels.

O'Brien SM, Scott LV, Dinan TG.

Br J Psychiatry. 2006 May;188:449-52.

16.

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M.

Neuropsychobiology. 2007;56(2-3):73-85. Epub 2007 Nov 23.

PMID:
18037817
17.

Clinical practice guidelines for depression in young people.

Jureidini JN, Tonkin AL.

Med J Aust. 2003 Mar 17;178(6):300; author reply 300-2. No abstract available.

PMID:
12633493
18.
20.

Remission of SSRI-induced akathisia after switch to nefazodone.

Chelben J, Strous RD, Lustig M, Baruch Y.

J Clin Psychiatry. 2001 Jul;62(7):570-1. No abstract available.

PMID:
11488371

Supplemental Content

Support Center